KPMG-INTERNATIONAL
13.12.2022 13:01:40 CET | Business Wire | Press release
KPMG International announces strong annual aggregated revenues for KPMG firms globally of US$35 billion for the fiscal year ending 30 September 2022 (FY22) — an increase of 14%.*
During continued economic and geopolitical uncertainty, robust numbers and consistent growth were achieved across all functions. Advisory achieved the largest growth increase — up 19% on FY21 across KPMG firms globally. Growth was driven by the success of Transaction and Deal Advisory services, as well as continued demand for innovative technologies and advanced cyber security solutions. Tax & Legal Services experienced 10% growth while Audit grew 8%, benefiting from a combination of the investments made in technology and our KPMG firms’ connected local knowledge.
“FY22 has been a strong year. KPMG firms’ financial performance validates an unwavering commitment to deliver services of the highest quality through a multi-disciplinary approach that helps provide solutions to clients’ most difficult challenges and the stability and resilience to invest, even in hard times.
But the true measure of our success is what we’ve been able to accomplish for those that rely on us most. Clients and wider society continue to face complex problems that require KPMG professionals to work across borders and disciplines and to collaborate more closely than ever. Few organizations have the expertise and global reach that KPMG has, and we’re at our best when we work together to inspire confidence and empower change.”
Bill Thomas, Global Chairman and CEO, KPMG International
Talent
The KPMG global organization’s worldwide headcount continues to grow, increasing by 12.4% in FY22, bolstered by more than 29,000 net new roles created. This growth has led to the addition of specialists and subject-matter experts at all levels, helping to enable high-quality and multi-disciplinary services designed to solve the complex problems of modern organizations around the world.
KPMG’s commitment to inclusion, diversity and equity (IDE) remains; women represent 48.5% of all KPMG professionals and we have achieved gender parity on the Global Management Team.
Bill Thomas commented: “This year’s growth will help us continue to invest in our people — which remains critical in a competitive marketplace for talent. Ensuring KPMG professionals are working on diverse projects that are making a positive difference and providing them with a flexible career path in an inclusive and caring environment are priorities for us. Keeping people motivated and happy is fundamental to success, and that’s why we’re so focused on the continued development of our culture that puts our purpose and Values at the heart of everything we do.”
Technology
The past year has seen the demand for technology-enabled transformation rise dramatically, reshaping many businesses, including our own. KPMG continues to make significant investments across the organization in digital transformation, including the appointment of Lisa Heneghan, as the Global Chief Digital Officer. Over the last year, KPMG professionals have helped clients transform their business model or processes, leading to more than 20% growth in revenue in this area from FY21 that is largely driven by digital transformation work — a testament to KPMG firms’ offerings: “Connected. Powered. Trusted. Elevate.” and the power of our alliance-driven digital solutions with globally recognized technology organizations.
Technology enables everything KPMG firms do as digital businesses and continues to drive investments in compliance and strategic tax advisory services. KPMG Digital Gateway, a cloud-native platform solution powered by Microsoft Azure, provides clients with access to a full suite of tax and legal technologies across 140 jurisdictions, helping organizations turn data into value when faced with huge shifts in the global tax policy and regulatory landscape.
More and more global organizations have looked to cloud technologies for growth opportunities, and through the power of our global delivery centers, the KPMG Delivery Network, KPMG firms have harnessed the agility and power of our global teams to extend the power and reach of technology solutions.
KPMG has invested significantly in our system of quality management throughout the organization, enabling compliance with new industry-wide global quality management standards. Following its rollout two years ago, KPMG Clara, our global, cloud-enabled, smart audit platform, also powered by Microsoft Azure, is used by nearly all 90,000 audit professionals across the 143 countries and territories that KPMG firms operate in.
KPMG Clara is an important step in KPMG’s journey to innovate and digitalize Audit. As part of our ongoing commitment to audit quality, consistency and innovation, the platform is a significant investment that integrates new and emerging technologies, with advanced capabilities that leverage data science, audit automation, and data visualization.
Environmental, social and governance (ESG)
ESG remains the watermark running through the organization and steady financial growth has underpinned investment in industry-leading global environmental, social and governance (ESG) solutions — in line with the US$1.5 billion investment commitment we made in 2021.
KPMG professionals’ focus on delivering multi-disciplinary client solutions to maximize the opportunities and address the challenges presented by the ESG agenda includes the creation of a global climate change and decarbonization hub to provide emerging technology expertise and decarbonization support and the launch of the sustainability reporting resource center to provide guidance in preparation for the International Sustainability Standards Board’s (ISSB) forthcoming Sustainability Disclosure Standards.
To date, almost 100,000 KPMG professionals have undertaken specialist ESG 101 training. This program, of learning for a lifetime, will continue.
For more on KPMG’s commitment to quality: KPMG International 2022 Transparency Report
For more of KPMG’s Corporate Highlights in FY22, including stories of KPMG professionals and how they’ve worked shoulder-to-shoulder with clients, visit: www.kpmg.com/corporatereporting
About KPMG International
KPMG is a global organization of independent professional services firms providing Audit, Tax and Advisory services. KPMG is the brand under which the member firms of KPMG International Limited (“KPMG International”) operate and provide professional services. “KPMG” is used to refer to individual member firms within the KPMG organization or to one or more member firms collectively.
KPMG firms operate in 143 countries and territories with more than 265,000 partners and employees working in member firms around the world. Each KPMG firm is a legally distinct and separate entity and describes itself as such. Each KPMG member firm is responsible for its own obligations and liabilities.
KPMG International Limited is a private English company limited by guarantee. KPMG International Limited and its related entities do not provide services to clients.
For more detail about our structure, please visit home.kpmg/governance.
ENDS
Notes to editors:
KPMG FY22 member firm revenues (US$ billions)
Regions |
FY22 |
FY21 |
Local
|
Americas |
13.71 |
11.88 |
16% |
Asia Pacific |
6.31 |
5.97 |
13% |
EMA |
14.62 |
14.28 |
11% |
Total |
34.64 |
32.13 |
13% |
Functions |
FY22 |
FY21 |
Local
|
Audit |
11.85 |
11.46 |
8% |
Tax and Legal Services |
7.35 |
7.02 |
10% |
Advisory |
15.44 |
13.65 |
19% |
Total |
34.64 |
32.13 |
13% |
*14% is based on the growth in continuing operations and excludes the FY21 and FY22 revenues from businesses sold or countries from which KPMG exited during this period. When not restated, the revenue growth is 13% and all other growth rates in this press release are similarly not restated, unless highlighted.
Further information
The financial information set out represents combined information of the independent KPMG member firms that perform professional services for clients, affiliated with KPMG International Limited. The information is combined here solely for presentation purposes. KPMG International Limited performs no services for clients nor, concomitantly, generates any client revenue.
FY22 revenues throughout this press release, reflect KPMG’s financial year between 1 October 2021 and 30 September 2022 and are based on US dollar gross revenues, including travel and other client reimbursable expenses. Local growth percentages are based on maintaining consistent FY22 exchange rates within the prior year.
Headcount reported above based on partners and staff employed as of 30 September 2022.
Legal services may not be offered to SEC registrant audit clients or where otherwise prohibited by law.
Throughout this press release, “we”, “KPMG”, “us” and “our” refers to the global organization or to one or more of the member firms of KPMG International Limited (“KPMG International”), each of which is a separate legal entity. KPMG International Limited is a private English company limited by guarantee and does not provide services to clients. No member firm has any authority to obligate or bind KPMG International or any other member firm vis-à-vis third parties, nor does KPMG International have any such authority to obligate or bind any member firm.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005319/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
